Advertisement
Screener

Korro Bio, Inc. (KRRO) Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value

Korro Bio, Inc. Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value

Korro Bio, Inc. (KRRO) had Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value of $2.79 million as of 2023-06-30, per its 10-Q filed 2023-08-10.

Discontinued › Notes › ASU 2016-13 Transition

us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2023-11-02

  • 2023-06-30: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value $2.79M.
  • 2023-03-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value $9.94M.
  • 2022-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value $9.93M.
  • 2021-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value $0.00.
Period endDebt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value
2023-06-30$2.79M
10-Q · filed 2023-08-10
2023-03-31$9.94M
10-Q · filed 2023-05-12
2022-12-31$9.93M
10-Q · filed 2023-11-02
2021-12-31$0.00
10-K · filed 2023-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atrium Therapeutics, Inc. (RNA)United States$0.140B
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88